{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:53:51Z","timestamp":1791244431466,"version":"4.1.0"},"reference-count":176,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007815","name":"District of Columbia Center for AIDS Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007815","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.diagmicrobio.2026.117492","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T15:31:27Z","timestamp":1780155087000},"page":"117492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antiviral resistance testing for DNA viruses in immunocompromised patients: Mechanisms, clinical utility, and limitations"],"prefix":"10.1016","volume":"116","author":[{"given":"Diego R","family":"Hijano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sree Sarah","family":"Cherian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne E","family":"Dale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7648-2037","authenticated-orcid":false,"given":"Meghan W","family":"Starolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.diagmicrobio.2026.117492_bib0001","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJM200302273480923","article-title":"Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient","volume":"348","author":"Weinstock","year":"2003","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2026.117492_bib0002","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003343","article-title":"Prolonged influenza virus shedding and emergence of antiviral resistance in immunocompromised patients and ferrets","volume":"9","author":"van der Vries","year":"2013","journal-title":"PLoS Pathog"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2026.117492_bib0003","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.idc.2010.01.001","article-title":"Antiviral drug resistance: mechanisms and clinical implications","volume":"24","author":"Strasfeld","year":"2010","journal-title":"Infect Dis Clin North Am"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117492_bib0004","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s44259-025-00125-z","article-title":"Strategies and efforts in circumventing the emergence of antiviral resistance against conventional antivirals","volume":"3","author":"Aw","year":"2025","journal-title":"NPJ Antimicrob Resist"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2026.117492_bib0005","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.00728-23","article-title":"Practical updates in clinical antiviral resistance testing","volume":"62","author":"Wang","year":"2024","journal-title":"J Clin Microbiol"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2026.117492_bib0006","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1086\/319231","article-title":"Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy","volume":"32","author":"Hanna","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117492_bib0007","doi-asserted-by":"crossref","DOI":"10.1093\/ve\/vew014","article-title":"Antiviral drug resistance as an adaptive process","volume":"2","author":"Irwin","year":"2016","journal-title":"Virus Evol"},{"key":"10.1016\/j.diagmicrobio.2026.117492_bib0008","author":"R"},{"key":"10.1016\/j.diagmicrobio.2026.117492_bib0010","unstructured":"Diagnostics Q. Hepatitis B Virus drug resistance, genotype, and BCP\/precore mutations; Available from: https:\/\/testdirectory.questdiagnostics.com\/test\/test-detail\/10529\/hepatitis-b-virus-drug-resistance-genotype-and-bcpprecore-mutations?cc=MASTER.]."},{"issue":"7","key":"10.1016\/j.diagmicrobio.2026.117492_bib0011","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.24963","article-title":"Prevalence of low-frequency, antiviral resistance variants in SARS-CoV-2 isolates in Ontario, Canada, 2020-2023","volume":"6","author":"Sjaarda","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"16","key":"10.1016\/j.diagmicrobio.2026.117492_bib0012","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2016-10-748426","article-title":"The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality","volume":"129","author":"Hill","year":"2017","journal-title":"Blood"},{"issue":"Suppl 4","key":"10.1016\/j.diagmicrobio.2026.117492_bib0013","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/ajt.12105","article-title":"Practice ASTIDCo. Herpes simplex virus in solid organ transplantation","volume":"13","author":"Wilck","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.diagmicrobio.2026.117492_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2022.101730","article-title":"Seroprevalence of VZV IgG antibody in kidney transplant recipients: A systematic and meta-analysis review","volume":"75","author":"Alimohammadi","year":"2022","journal-title":"Transpl Immunol"},{"issue":"10","key":"10.1016\/j.diagmicrobio.2026.117492_bib0015","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.bbmt.2014.06.002","article-title":"Varicella-zoster reactivation after allogeneic stem cell transplantation without routine prophylaxis\u2013the incidence remains high","volume":"20","author":"Blennow","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117492_bib0016","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3390\/pathogens14010050","article-title":"Cytomegalovirus genetic diversity and evolution: insights into genotypes and their role in viral pathogenesis","volume":"14","author":"Venturini","year":"2025","journal-title":"Pathogens"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2026.117492_bib0017","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/QCO.0000000000000592","article-title":"Human herpesvirus 6 in transplant recipients: an update on diagnostic and treatment strategies","volume":"32","author":"Hill","year":"2019","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2026.117492_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1059133","article-title":"EBV-associated diseases: current therapeutics and emerging technologies","volume":"13","author":"Chakravorty","year":"2022","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2026.117492_bib0019","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac395","article-title":"Seropositivity, risks, and morbidity from Varicella-zoster virus infections in an adult PWH cohort from 2000-2020","volume":"9","author":"Zou","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2026.117492_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105623","article-title":"Prevalence of cytomegalovirus antiviral drug resistance in transplant recipients","volume":"215","author":"Kleiboeker","year":"2023","journal-title":"Antiviral Res"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117492_bib0021","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s13054-024-05029-4","article-title":"Clinical characteristics and outcomes of immunocompromised critically ill patients with cytomegalovirus end-organ disease: a multicenter retrospective cohort study","volume":"28","author":"Fernandez","year":"2024","journal-title":"Crit Care"},{"issue":"Suppl 2","key":"10.1016\/j.diagmicrobio.2026.117492_bib0022","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1034\/j.1399-3062.2001.00004.x","article-title":"Cytomegalovirus drug resistance and clinical implications","volume":"3","author":"Chou","year":"2001","journal-title":"Transpl Infect Dis"},{"issue":"7","key":"10.1016\/j.diagmicrobio.2026.117492_bib0104","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1128\/AAC.00511-13","article-title":"Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance","volume":"57","author":"Chou","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2026.117492_bib0105","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.csbj.2015.01.003","article-title":"Antiviral drug- and multidrug resistance in Cytomegalovirus infected SCT patients","volume":"13","author":"Gohring","year":"2015","journal-title":"Comput Struct Biotechnol J"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2026.117492_bib0106","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1093\/infdis\/jiae469","article-title":"Comparative emergence of Maribavir and Ganciclovir resistance in a randomized phase 3 clinical trial for treatment of Cytomegalovirus infection","volume":"231","author":"Chou","year":"2025","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2026.117492_bib0107","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1128\/CMR.12.2.286","article-title":"Resistance of human cytomegalovirus to antiviral drugs","volume":"12","author":"Erice","year":"1999","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2026.117492_bib0108","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1128\/AAC.00186-10","article-title":"Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance","volume":"54","author":"Chou","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117492_bib0109","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00705-012-1479-4","article-title":"A new mutation in the human cytomegalovirus UL97 gene may confer ganciclovir resistance in Chinese kidney transplant recipients","volume":"158","author":"Zhang","year":"2013","journal-title":"Arch Virol"},{"issue":"7","key":"10.1016\/j.diagmicrobio.2026.117492_bib0110","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1128\/JCM.00391-17","article-title":"Differentiated levels of ganciclovir resistance conferred by mutations at codons 591 to 603 of the Cytomegalovirus UL97 kinase gene","volume":"55","author":"Chou","year":"2017","journal-title":"J Clin Microbiol"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2026.117492_bib0111","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1128\/AAC.45.2.593-595.2001","article-title":"Emergence of multiple human cytomegalovirus ganciclovir-resistant mutants with deletions and substitutions within the UL97 gene in a patient with severe combined immunodeficiency","volume":"45","author":"Wolf","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117492_bib0112","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1128\/AAC.44.1.183-185.2000","article-title":"A nine-codon deletion mutation in the cytomegalovirus UL97 phosphotransferase gene confers resistance to ganciclovir","volume":"44","author":"Chou","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2026.117492_bib0113","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1086\/338362","article-title":"Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir","volume":"185","author":"Chou","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2026.117492_bib0114","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jcv.2015.06.090","article-title":"Identification of newly detected, drug-related HCMV UL97- and UL54-mutations using a modified plaque reduction assay","volume":"69","author":"Fischer","year":"2015","journal-title":"J Clin Virol"},{"issue":"7","key":"10.1016\/j.diagmicrobio.2026.117492_bib0025","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1097\/TP.0000000000005374","article-title":"The Fourth International Consensus Guidelines on the management of Cytomegalovirus in solid organ transplantation","volume":"109","author":"Kotton","year":"2025","journal-title":"Transplantation"},{"issue":"1-2","key":"10.1016\/j.diagmicrobio.2026.117492_bib0115","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0166-3542(98)00051-5","article-title":"Genetic analysis of a ganciclovir-resistant human cytomegalovirus mutant","volume":"40","author":"Faizi Khan","year":"1998","journal-title":"Antiviral Res"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2026.117492_bib0116","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1086\/342844","article-title":"Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients","volume":"186","author":"Lurain","year":"2002","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2026.117492_bib0117","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The Third International Consensus Guidelines on the management of Cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2026.117492_bib0118","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jcv.2006.11.005","article-title":"Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients","volume":"38","author":"Marfori","year":"2007","journal-title":"J Clin Virol"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2026.117492_bib0119","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus","volume":"23","author":"Lurain","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.diagmicrobio.2026.117492_bib0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104616","article-title":"Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","volume":"172","author":"Chou","year":"2019","journal-title":"Antiviral Res"},{"key":"10.1016\/j.diagmicrobio.2026.117492_bib0121","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105139","article-title":"Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing","volume":"193","author":"Chou","year":"2021","journal-title":"Antiviral Res"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2026.117492_bib0122","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/infdis\/jiaa462","article-title":"Drug resistance mutations and associated phenotypes detected in clinical trials of Maribavir for treatment of Cytomegalovirus infection","volume":"226","author":"Chou","year":"2022","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2026.117492_bib0123","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0166-3542(01)00202-9","article-title":"GCV resistance due to the mutation A594P in the cytomegalovirus protein UL97 is partially reconstituted by a second mutation at D605E","volume":"53","author":"Ijichi","year":"2002","journal-title":"Antiviral Res"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2026.117492_bib0124","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02425-18","article-title":"Patient-derived cytomegaloviruses with different ganciclovir sensitivities from UL97 mutation retain their replication efficiency and some kinase activity In vitro","volume":"63","author":"Wong","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2026.117492_bib0029","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/infdis\/jiad293","article-title":"Drug resistance assessed in a phase 3 clinical trial of Maribavir Therapy for refractory or resistant Cytomegalovirus infection in transplant recipients","volume":"229","author":"Chou","year":"2024","journal-title":"J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2026.117492_bib0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2016.04.002","article-title":"Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance","volume":"131","author":"Fischer","year":"2016","journal-title":"Antiviral Res"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2026.117492_bib0126","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1086\/317931","article-title":"Mutations conferring ganciclovir resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis","volume":"183","author":"Jabs","year":"2001","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2026.117492_bib0127","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.antiviral.2013.09.026","article-title":"Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation","volume":"100","author":"Fischer","year":"2013","journal-title":"Antiviral Res"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117492_bib0128","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1086\/375743","article-title":"Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus","volume":"188","author":"Chou","year":"2003","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117492_bib0129","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.antiviral.2013.02.002","article-title":"Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model","volume":"98","author":"Hantz","year":"2013","journal-title":"Antiviral Res"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2026.117492_bib0130","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jcv.2011.01.004","article-title":"Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy","volume":"50","author":"Chou","year":"2011","journal-title":"J Clin Virol"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2026.117492_bib0131","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/QCO.0000000000000170","article-title":"Approach to drug-resistant cytomegalovirus in transplant recipients","volume":"28","author":"Chou","year":"2015","journal-title":"Curr Opin Infect Dis"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2026.117492_bib0132","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1128\/AAC.00214-16","article-title":"Novel Cytomegalovirus UL54 DNA polymerase gene mutations selected In vitro that confer brincidofovir resistance","volume":"60","author":"Chou","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2026.117492_bib0133","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1128\/AAC.00334-11","article-title":"Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet","volume":"55","author":"Gilbert","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2026.117492_bib0134","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1368-7646(02)00021-3","article-title":"Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms","volume":"5","author":"Gilbert","year":"2002","journal-title":"Drug Resist Updat"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2026.117492_bib0135","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1093\/infdis\/jit654","article-title":"Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial","volume":"209","author":"Chou","year":"2014","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.diagmicrobio.2026.117492_bib0136","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1128\/JVI.72.7.5927-5936.1998","article-title":"Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments","volume":"72","author":"Cihlar","year":"1998","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2026.117492_bib0137","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1006\/viro.1998.9299","article-title":"A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture","volume":"248","author":"Cihlar","year":"1998","journal-title":"Virology"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2026.117492_bib0138","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1128\/AAC.03214-14","article-title":"Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing","volume":"58","author":"Chou","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.diagmicrobio.2026.117492_bib0139","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1111\/ajt.15135","article-title":"Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection","volume":"18","author":"Cherrier","year":"2018","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117492_bib0140","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jcv.2008.04.005","article-title":"Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus","volume":"43","author":"Chou","year":"2008","journal-title":"J Clin Virol"},{"issue":"11","key":"10.1016\/j.diagmicrobio.2026.117492_bib0141","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1128\/JCM.02205-14","article-title":"Characterization of multiple cytomegalovirus drug resistance mutations detected in a hematopoietic stem cell transplant recipient by recombinant phenotyping","volume":"52","author":"Drouot","year":"2014","journal-title":"J Clin Microbiol"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2026.117492_bib0142","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/QCO.0b013e32834cfb58","article-title":"The biology of cytomegalovirus drug resistance","volume":"24","author":"Hakki","year":"2011","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2026.117492_bib0143","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2025.106340","article-title":"A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials","volume":"246","author":"Chou","year":"2026","journal-title":"Antiviral Res"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2026.117492_bib0023","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1093\/infdis\/jiac349","article-title":"Genotypic and phenotypic study of antiviral resistance mutations in refractory Cytomegalovirus infection","volume":"226","author":"Santos Bravo","year":"2022","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117492_bib0144","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1128\/JCM.43.1.208-213.2005","article-title":"How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients","volume":"43","author":"Springer","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2026.117492_bib0145","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.771978","article-title":"Analysis of novel drug-resistant Human Cytomegalovirus DNA polymerase mutations reveals the role of a DNA-binding loop in phosphonoformic acid resistance","volume":"13","author":"Park","year":"2022","journal-title":"Front Microbiol"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2026.117492_bib0146","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1093\/infdis\/jiz298","article-title":"Compartmentalization of a multidrug-resistant Cytomegalovirus UL54 mutant in a stem cell transplant recipient with encephalitis","volume":"220","author":"Piret","year":"2019","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2026.117492_bib0051","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1128\/JVI.80.3.1440-1450.2006","article-title":"Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to the antiviral drug foscarnet","volume":"80","author":"Tchesnokov","year":"2006","journal-title":"J Virol"},{"issue":"11","key":"10.1016\/j.diagmicrobio.2026.117492_bib0147","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1128\/AAC.00736-07","article-title":"Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens","volume":"51","author":"Chou","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117492_bib0148","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1128\/AAC.00633-06","article-title":"Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates","volume":"51","author":"Scott","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2026.117492_bib0149","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1086\/317618","article-title":"A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance","volume":"182","author":"Chou","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2026.117492_bib0150","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.antiviral.2016.12.003","article-title":"Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","volume":"138","author":"Chou","year":"2017","journal-title":"Antiviral Res"},{"key":"10.1016\/j.diagmicrobio.2026.117492_bib0151","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.antiviral.2016.02.004","article-title":"Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: benefits and limits of 3D analysis","volume":"129","author":"Andouard","year":"2016","journal-title":"Antiviral Res"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117492_bib0028","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1128\/AAC.01177-08","article-title":"Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir","volume":"53","author":"Chou","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.diagmicrobio.2026.117492_bib0152","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01325-17","article-title":"Comparison of Cytomegalovirus terminase gene mutations selected after exposure to three distinct inhibitor compounds","volume":"61","author":"Chou","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2026.117492_bib0153","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41409-023-01920-w","article-title":"Cytomegalovirus breakthrough and resistance during letermovir prophylaxis","volume":"58","author":"Perchetti","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2026.117492_bib0154","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00922-18","article-title":"New locus of drug resistance in the Human Cytomegalovirus UL56 gene revealed by In vitro exposure to Letermovir and Ganciclovir","volume":"62","author":"Chou","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117492_bib0155","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/infdis\/jiv352","article-title":"Characterization of Cytomegalovirus breakthrough events in a phase 2 prophylaxis trial of Letermovir (AIC246, MK 8228)","volume":"213","author":"Lischka","year":"2016","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2026.117492_bib0048","doi-asserted-by":"crossref","first-page":"5863","DOI":"10.1128\/JVI.79.9.5863-5869.2005","article-title":"Characterization of herpes simplex virus type 1 thymidine kinase mutants selected under a single round of high-dose brivudin","volume":"79","author":"Andrei","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.diagmicrobio.2026.117492_bib0156","doi-asserted-by":"crossref","DOI":"10.1038\/srep29903","article-title":"Recombinant herpes simplex virus type 1 strains with targeted mutations relevant for aciclovir susceptibility","volume":"6","author":"Brunnemann","year":"2016","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.diagmicrobio.2026.117492_bib0157","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1128\/AAC.00889-06","article-title":"Thymidine kinase mutations conferring acyclovir resistance in herpes simplex type 1 recombinant viruses","volume":"50","author":"Sergerie","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2026.117492_bib0158","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.antiviral.2006.01.010","article-title":"Intracellular uptake of thymidine and antiherpetic drugs for thymidine kinase-deficient mutants of herpes simplex virus type 1","volume":"70","author":"Bae","year":"2006","journal-title":"Antiviral Res"},{"issue":"7","key":"10.1016\/j.diagmicrobio.2026.117492_bib0159","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1128\/JVI.75.7.3105-3110.2001","article-title":"Highly reliable heterologous system for evaluating resistance of clinical herpes simplex virus isolates to nucleoside analogues","volume":"75","author":"Bestman-Smith","year":"2001","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2026.117492_bib0160","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0166-3542(02)00131-6","article-title":"Genotypic and phenotypic characterization of the thymidine kinase of ACV-resistant HSV-1 derived from an acyclovir-sensitive herpes simplex virus type 1 strain","volume":"56","author":"Saijo","year":"2002","journal-title":"Antiviral Res"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2026.117492_bib0161","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1128\/AAC.00977-15","article-title":"Sequence analysis of Herpes Simplex virus 1 thymidine kinase and DNA polymerase genes from over 300 clinical isolates from 1973 to 2014 finds novel mutations that may Be relevant for development of antiviral resistance","volume":"59","author":"Schmidt","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2026.117492_bib0162","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1128\/AAC.49.2.606-611.2005","article-title":"Genotypic characterization of the DNA polymerase and sensitivity to antiviral compounds of foscarnet-resistant herpes simplex virus type 1 (HSV-1) derived from a foscarnet-sensitive HSV-1 strain","volume":"49","author":"Saijo","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"14","key":"10.1016\/j.diagmicrobio.2026.117492_bib0163","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1128\/JVI.77.14.7820-7829.2003","article-title":"Drug resistance patterns of recombinant herpes simplex virus DNA polymerase mutants generated with a set of overlapping cosmids and plasmids","volume":"77","author":"Bestman-Smith","year":"2003","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2026.117492_bib0164","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1177\/135965350701200502","article-title":"DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions","volume":"12","author":"Andrei","year":"2007","journal-title":"Antivir Ther"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2026.117492_bib0165","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.antiviral.2013.09.008","article-title":"Phenotypic and genotypic characterization of induced acyclovir-resistant clinical isolates of herpes simplex virus type 1","volume":"100","author":"Hussin","year":"2013","journal-title":"Antiviral Res"},{"issue":"7","key":"10.1016\/j.diagmicrobio.2026.117492_bib0166","doi-asserted-by":"crossref","first-page":"962","DOI":"10.3390\/v17070962","article-title":"Primary HSV-2 infection in an immunocompromised patient reveals high diversity of drug-resistance mutations in the viral DNA polymerase","volume":"17","author":"Schalkwijk","year":"2025","journal-title":"Viruses"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2026.117492_bib0167","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1128\/AAC.05115-14","article-title":"Drug resistance of clinical varicella-zoster virus strains confirmed by recombinant thymidine kinase expression and by targeted resistance mutagenesis of a cloned wild-type isolate","volume":"59","author":"Brunnemann","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117492_bib0024","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12985-023-02127-7","article-title":"Cytomegalovirus drug resistance mutations in transplant recipients with suspected resistance","volume":"20","author":"Recio","year":"2023","journal-title":"Virol J"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117492_bib0026","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13696","article-title":"Maribavir: mechanism of action, clinical, and translational science","volume":"17","author":"Sun","year":"2024","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.diagmicrobio.2026.117492_bib0027","first-page":"111","article-title":"Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients","volume":"4","author":"Patil","year":"2010","journal-title":"Clin Ophthalmol"},{"issue":"10","key":"10.1016\/j.diagmicrobio.2026.117492_bib0030","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.00429-23","article-title":"Use of next-generation sequencing to detect mutations associated with antiviral drug resistance in cytomegalovirus","volume":"61","author":"Streck","year":"2023","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2026.117492_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105422","article-title":"Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing","volume":"207","author":"Chou","year":"2022","journal-title":"Antiviral Res"},{"issue":"12","key":"10.1016\/j.diagmicrobio.2026.117492_bib0032","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.00829-23","article-title":"Development and validation of a next-generation sequencing assay with open-access analysis software for detecting resistance-associated mutations in CMV","volume":"61","author":"Mallory","year":"2023","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2026.117492_bib0033","unstructured":"Laboratories A. Cytomegalovirus drug resistance by Next Generation sequencing; Available from: https:\/\/www.aruplab.com\/infectious-disease\/cytomegalovirus."},{"key":"10.1016\/j.diagmicrobio.2026.117492_bib0057","unstructured":"Laboratories A. Antiviral susceptibility, Herpes Simplex virus, Foscarnet; Available from: https:\/\/ltd.aruplab.com\/Tests\/Pub\/2010785?_gl=1*rp5no8*_ga*MTQwNDY1MTkwNS4xNzU0MzIxNjkz*_ga_Z8H49DQE4D*czE3NjI5NjE2NjQkbzEyJGcxJHQxNzYyOTYyMDI0JGo2MCRsMCRoMA..&_ga=2.105620864.2089933784.1762961664-1404651905.1754321693.]."},{"key":"10.1016\/j.diagmicrobio.2026.117492_bib0058","unstructured":"Laboratories A. Antiviral susceptibility, Herpes Simplex virus, Acyclovir; Available from: https:\/\/ltd.aruplab.com\/Tests\/Pub\/2010866?_ga=2.176384550.2089933784.1762961664-1404651905.1754321693&_gl=1*7axd4t*_ga*MTQwNDY1MTkwNS4xNzU0MzIxNjkz*_ga_Z8H49DQE4D*czE3NjI5NjE2NjQkbzEyJGcxJHQxNzYyOTYxNzIwJGo0JGwwJGgw.]."},{"key":"10.1016\/j.diagmicrobio.2026.117492_bib0059","unstructured":"Labcorp. Herpes simplex virus (HSV) types 1\/2 phenotyping for acyclovir drug resistance; Available from: https:\/\/www.labcorp.com\/tests\/138370\/herpes-simplex-virus-hsv-types-1-2-phenotyping-for-acyclovir-drug-resistance.]."},{"key":"10.1016\/j.diagmicrobio.2026.117492_bib0060","unstructured":"Washington LMPoUo. HSV acyclovir drug resistance by sanger sequencing; Available from: https:\/\/testguide.labmed.uw.edu\/view\/HSVDR.]."},{"key":"10.1016\/j.diagmicrobio.2026.117492_bib0034","unstructured":"eurofins-Viracor. Innovations in resistance: CMV antiviral resistance diagnostics; Available from: https:\/\/www.eurofins-viracor.com\/our-testing\/cmv-resistance\/.]."},{"key":"10.1016\/j.diagmicrobio.2026.117492_bib0035","unstructured":"Diagnostics Q. Cytomegalovirus (CMV) genotype; Available from: https:\/\/testdirectory.questdiagnostics.com\/test\/test-guides\/TS_CMV_Genotype\/cytomegalovirus-cmv-genotype.]."},{"issue":"10","key":"10.1016\/j.diagmicrobio.2026.117492_bib0036","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1001\/jama.2024.12743","article-title":"Genital Herpes","volume":"332","author":"Johnston","year":"2024","journal-title":"JAMA, J Am Med Assoc"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2026.117492_bib0037","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1001\/jamainternmed.2019.5713","article-title":"Acyclovir for mechanically ventilated patients with Herpes simplex virus oropharyngeal reactivation: A randomized clinical trial","volume":"180","author":"Luyt","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2026.117492_bib0038","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1001\/archdermatol.2009.363","article-title":"Successful treatment of acyclovir-resistant herpes simplex virus with intralesional cidofovir","volume":"146","author":"Castelo-Soccio","year":"2010","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2026.117492_bib0039","article-title":"Compounded topical cidofovir as salvage therapy for acyclovirresistant genital HSV-2 in an immunocompromised pregnant patient","volume":"4","author":"Veltri","year":"2025","journal-title":"Clin Med Res Stud"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2026.117492_bib0040","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00017-19","article-title":"Differences in the likelihood of acyclovir resistance-associated mutations in the thymidine kinase genes of herpes simplex virus 1 and varicella-zoster virus","volume":"63","author":"Fujii","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117492_bib0041","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1128\/CMR.16.1.114-128.2003","article-title":"Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy","volume":"16","author":"Bacon","year":"2003","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2026.117492_bib0042","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1128\/AAC.00615-10","article-title":"Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management","volume":"55","author":"Piret","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.diagmicrobio.2026.117492_bib0043","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.3390\/v2122803","article-title":"Cidofovir activity against poxvirus infections","volume":"2","author":"Andrei","year":"2010","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2026.117492_bib0044","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3390\/v15020439","article-title":"Herpes simplex virus and Varicella zoster virus infections in cancer patients","volume":"15","author":"Tayyar","year":"2023","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117492_bib0045","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jcv.2004.04.002","article-title":"Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization","volume":"32","author":"Stranska","year":"2005","journal-title":"J Clin Virol"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2026.117492_bib0046","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1128\/JCM.39.3.913-917.2001","article-title":"Frequency of acyclovir-resistant herpes simplex virus in clinical specimens and laboratory isolates","volume":"39","author":"Shin","year":"2001","journal-title":"J Clin Microbiol"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2026.117492_bib0047","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155531","article-title":"Prevalence of intrathecal acyclovir resistant virus in Herpes simplex encephalitis patients","volume":"11","author":"Mitterreiter","year":"2016","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.diagmicrobio.2026.117492_bib0049","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1128\/AAC.00669-10","article-title":"Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals","volume":"54","author":"Burrel","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"20","key":"10.1016\/j.diagmicrobio.2026.117492_bib0050","article-title":"Distribution and effects of amino acid changes in drug-resistant alpha and beta herpesviruses DNA polymerase","volume":"44","author":"Topalis","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.diagmicrobio.2026.117492_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115322","article-title":"Acyclovir resistance in herpes simplex viruses: prevalence and therapeutic alternatives","volume":"206","author":"Schalkwijk","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.diagmicrobio.2026.117492_bib0053","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jcv.2017.10.002","article-title":"A European multi-centre External Quality Assessment (EQA) study on phenotypic and genotypic methods used for Herpes Simplex Virus (HSV) drug resistance testing","volume":"96","author":"Afshar","year":"2017","journal-title":"J Clin Virol"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2026.117492_bib0054","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.cmi.2025.04.046","article-title":"Herpes simplex virus and drug resistance-comprehensive update on resistance mutations and implications for clinical management: a narrative review","volume":"31","author":"Dahne","year":"2025","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2026.117492_bib0055","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1128\/AAC.38.6.1246","article-title":"Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients","volume":"38","author":"Safrin","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2026.117492_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2023.105554","article-title":"Genotypic testing improves detection of antiviral resistance in human herpes simplex virus","volume":"167","author":"Glasgow","year":"2023","journal-title":"J Clin Virol"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2026.117492_bib0061","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bbmt.2010.06.020","article-title":"Treatment of acyclovir-resistant herpes simplex virus with continuous infusion of high-dose acyclovir in hematopoietic cell transplant patients","volume":"17","author":"Kim","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2026.117492_bib0062","doi-asserted-by":"crossref","first-page":"555","DOI":"10.4161\/viru.1.6.13806","article-title":"Testing of herpes simplex virus for resistance to antiviral drugs","volume":"1","author":"Sauerbrei","year":"2010","journal-title":"Virulence"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117492_bib0063","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/jac\/dkv285","article-title":"Database on natural polymorphisms and resistance-related non-synonymous mutations in thymidine kinase and DNA polymerase genes of herpes simplex virus types 1 and 2","volume":"71","author":"Sauerbrei","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2026.117492_bib0064","unstructured":"Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: Herpes Simplex virus. Clinical info HIV.Gov; 2025."},{"issue":"2","key":"10.1016\/j.diagmicrobio.2026.117492_bib0065","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.tripleo.2009.08.037","article-title":"Low prevalence of varicella zoster virus and herpes simplex virus type 2 in saliva from human immunodeficiency virus-infected persons in the era of highly active antiretroviral therapy","volume":"109","author":"Wang","year":"2010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.diagmicrobio.2026.117492_bib0066","author":"RJ"},{"key":"10.1016\/j.diagmicrobio.2026.117492_bib0067","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3899\/jrheum.2025-0016","article-title":"Varicella Zoster virus vaccination in patients with immune-mediated inflammatory diseases: drivers and barriers","volume":"52","author":"Goulenok","year":"2025","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2026.117492_bib0068","doi-asserted-by":"crossref","first-page":"80","DOI":"10.15585\/mmwr.mm7103a2","article-title":"Use of recombinant zoster vaccine in immunocompromised adults aged >\/=19 years: recommendations of the Advisory Committee on Immunization Practices - United States, 2022","volume":"71","author":"Anderson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"17","key":"10.1016\/j.diagmicrobio.2026.117492_bib0069","first-page":"2062","article-title":"How I prevent viral reactivation in high-risk patients","volume":"141","author":"Dadwal","year":"2023","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.diagmicrobio.2026.117492_bib0070","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1093\/infdis\/166.Supplement_1.S13","article-title":"Comparative biology of latent varicella-zoster virus and herpes simplex virus infections","volume":"166","author":"Meier","year":"1992","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2026.117492_bib0071","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.antiviral.2011.04.005","article-title":"Resistance testing of clinical varicella-zoster virus strains","volume":"90","author":"Sauerbrei","year":"2011","journal-title":"Antiviral Res"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117492_bib0072","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1128\/CMR.18.1.217-245.2005","article-title":"Update on human herpesvirus 6 biology, clinical features, and therapy","volume":"18","author":"De Bolle","year":"2005","journal-title":"Clin Microbiol Rev"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2026.117492_bib0073","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00705-013-1902-5","article-title":"Classification of HHV-6A and HHV-6B as distinct viruses","volume":"159","author":"Ablashi","year":"2014","journal-title":"Arch Virol"},{"issue":"10","key":"10.1016\/j.diagmicrobio.2026.117492_bib0074","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.cmi.2022.02.001","article-title":"Assessing and restoring adaptive immunity to HSV, VZV, and HHV-6 in solid organ and hematopoietic cell transplant recipients","volume":"28","author":"Heldman","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"10.1016\/j.diagmicrobio.2026.117492_bib0075","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1086\/339411","article-title":"Human herpesvirus 6 viremia in bone marrow transplant recipients: clinical features and risk factors","volume":"185","author":"Yoshikawa","year":"2002","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117492_bib0076","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1038\/s41598-019-40372-5","article-title":"Identification of CD4 and H-2K(d)-restricted cytotoxic T lymphocyte epitopes on the human herpesvirus 6B glycoprotein Q1 protein","volume":"9","author":"Nagamata","year":"2019","journal-title":"Sci Rep"},{"issue":"Pt 11","key":"10.1016\/j.diagmicrobio.2026.117492_bib0078","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1099\/0022-1317-82-11-2767","article-title":"Selection of the same mutation in the U69 protein kinase gene of human herpesvirus-6 after prolonged exposure to ganciclovir in vitro and in vivo","volume":"82","author":"Manichanh","year":"2001","journal-title":"J Gen Virol"},{"key":"10.1016\/j.diagmicrobio.2026.117492_bib0079","unstructured":"Foundation H-. New standardized approach to the evaluation of antivirals for DNA viruses; 2018. [Accessed November 11 2018]."},{"key":"10.1016\/j.diagmicrobio.2026.117492_bib0080","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.antiviral.2018.09.016","article-title":"A standardized approach to the evaluation of antivirals against DNA viruses: polyomaviruses and lymphotropic herpesviruses","volume":"159","author":"Keith","year":"2018","journal-title":"Antiviral Res"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117492_bib0081","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jcv.2008.09.002","article-title":"Human herpesvirus 6 ganciclovir-resistant strain with amino acid substitutions associated with the death of an allogeneic stem cell transplant recipient","volume":"44","author":"Isegawa","year":"2009","journal-title":"J Clin Virol"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2026.117492_bib0084","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/cid\/cix804","article-title":"Kinetics of double-stranded DNA viremia after allogeneic hematopoietic cell transplantation","volume":"66","author":"Hill","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2026.117492_bib0085","doi-asserted-by":"crossref","first-page":"505.e1","DOI":"10.1016\/j.jtct.2021.02.021","article-title":"Economic and clinical burden of virus-associated hemorrhagic cystitis in patients following allogeneic hematopoietic stem cell transplantation in the United States","volume":"27","author":"McGuirk","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.diagmicrobio.2026.117492_bib0082","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/750836","article-title":"BK virus in kidney transplant recipients: the influence of immunosuppression","volume":"2011","author":"Barraclough","year":"2011","journal-title":"J Transplant"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2026.117492_bib0083","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1128\/CMR.00074-16","article-title":"BK polyomavirus: clinical aspects, immune regulation, and emerging therapies","volume":"30","author":"Ambalathingal","year":"2017","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2026.117492_bib0086","doi-asserted-by":"crossref","first-page":"309","DOI":"10.5500\/wjt.v13.i6.309","article-title":"BK viral infection: A review of management and treatment","volume":"13","author":"Gorriceta","year":"2023","journal-title":"World J Transplant"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2026.117492_bib0087","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1097\/TP.0000000000004976","article-title":"The Second International Consensus Guidelines on the management of BK polyomavirus in kidney transplantation","volume":"108","author":"Kotton","year":"2024","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2026.117492_bib0088","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00005-011-0148-8","article-title":"Disseminated adenovirus disease in immunocompromised patient successfully treated with oral ribavirin: a case report","volume":"59","author":"Ulrych","year":"2011","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"10.1016\/j.diagmicrobio.2026.117492_bib0089","article-title":"Human Adenovirus associated hepatic injury","volume":"10","author":"Zheng","year":"2022","journal-title":"Front Public Health"},{"issue":"39","key":"10.1016\/j.diagmicrobio.2026.117492_bib0090","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.15585\/mmwr.mm6639a2","article-title":"Human adenovirus surveillance - United States, 2003-2016","volume":"66","author":"Binder","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2026.117492_bib0091","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3390\/v17050599","article-title":"Treating Adenovirus infection in transplant populations: therapeutic options beyond Cidofovir?","volume":"17","author":"Narsana","year":"2025","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117492_bib0092","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1684\/vir.2021.0883","article-title":"Which drugs to treat Adenovirus infections?","volume":"25","author":"Salmona","year":"2021","journal-title":"Virologie (Montrouge)"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117492_bib0093","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0166-3542(02)00098-0","article-title":"Sequence changes in the human adenovirus type 5 DNA polymerase associated with resistance to the broad spectrum antiviral cidofovir","volume":"56","author":"Kinchington","year":"2002","journal-title":"Antiviral Res"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2026.117492_bib0094","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036673","article-title":"Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients","volume":"7","author":"Delaugerre","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2026.117492_bib0095","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/infdis\/jir353","article-title":"Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy","volume":"204","author":"Taiwo","year":"2011","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.diagmicrobio.2026.117492_bib0096","doi-asserted-by":"crossref","first-page":"ofz480","DOI":"10.1093\/ofid\/ofz480","article-title":"Analysis of Ganciclovir-resistant Cytomegalovirus infection caused by the UL97 gene mutation in codons 460 and 520 in pediatric patients: a case series","volume":"6","author":"Boonsathorn","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2026.117492_bib0097","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1007\/s10875-021-01205-1","article-title":"Antiviral T-cell frequencies in a healthy population: reference values for evaluating Antiviral immune cell profiles in immunocompromised patients","volume":"42","author":"Schulze Lammers","year":"2022","journal-title":"J Clin Immunol"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2026.117492_bib0098","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/jac\/dkae482","article-title":"Efficacy and safety of antiviral therapies for the treatment of persistent COVID-19 in immunocompromised patients since the Omicron surge: a systematic review","volume":"80","author":"Hirsch","year":"2025","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2026.117492_bib0099","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00905-24","article-title":"Efficacy of late-onset antiviral treatment in immunocompromised hosts with persistent SARS-CoV-2 infection","volume":"98","author":"Lieber","year":"2024","journal-title":"J Virol"},{"issue":"7","key":"10.1016\/j.diagmicrobio.2026.117492_bib0100","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1097\/CCM.0000000000000969","article-title":"Coreactivation of Human herpesvirus 6 and Cytomegalovirus is associated with worse clinical outcome in critically ill adults","volume":"43","author":"Lopez Roa","year":"2015","journal-title":"Crit Care Med"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2026.117492_bib0101","article-title":"Cytomegalovirus and Herpes simplex virus Co-infection in an HIV-negative patient: A case report","volume":"13","author":"Gangemi","year":"2021","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117492_bib0102","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12985-020-01302-4","article-title":"Co-infections of human herpesviruses (CMV, HHV-6, HHV-7 and EBV) in non-transplant acute leukemia patients undergoing chemotherapy","volume":"17","author":"Handous","year":"2020","journal-title":"Virol J"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2026.117492_bib0103","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.9089","article-title":"Varicella zoster virus and cytomegalovirus coinfection in a live related kidney transplant recipient: A case report","volume":"12","author":"Bari","year":"2024","journal-title":"Clin Case Rep"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2026.117492_fur1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.antiviral.2012.05.013","article-title":"Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo","volume":"95","author":"Chou","year":"2012","journal-title":"Antiviral Res"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117492_fur2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1086\/518514","article-title":"Cytomegalovirus UL97 kinase mutations that confer maribavir resistance","volume":"196","author":"Chou","year":"2007","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2026.117492_fur3","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jcv.2006.07.010","article-title":"Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet","volume":"37","author":"Drew","year":"2006","journal-title":"J Clin Virol"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117492_fur4","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1128\/AAC.01726-13","article-title":"Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions","volume":"58","author":"Komazin-Meredith","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2026.117492_fur5","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/(SICI)1096-9071(199908)58:4<402::AID-JMV13>3.0.CO;2-5","article-title":"Quantitative changes in cytomegalovirus DNAemia and genetic analysis of the UL97 and UL54 genes in AIDS patients receiving cidofovir following ganciclovir therapy","volume":"58","author":"Bowen","year":"1999","journal-title":"J Med Virol"},{"key":"10.1016\/j.diagmicrobio.2026.117492_fur6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.antiviral.2016.09.012","article-title":"The D-form of a novel heparan binding peptide decreases cytomegalovirus infection in vivo and in vitro","volume":"135","author":"Pitt","year":"2016","journal-title":"Antiviral Res"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2026.117492_fur7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1386-6532(02)00046-X","article-title":"Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","volume":"26","author":"Mousavi-Jazi","year":"2003","journal-title":"J Clin Virol"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2026.117492_fur8","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.humimm.2004.02.007","article-title":"Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs","volume":"65","author":"Baldanti","year":"2004","journal-title":"Hum Immunol"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117492_fur9","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1128\/AAC.05559-11","article-title":"Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure","volume":"56","author":"Chou","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2026.117492_fur10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2017.10.019","article-title":"A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance","volume":"148","author":"Chou","year":"2017","journal-title":"Antiviral Res"},{"issue":"10","key":"10.1016\/j.diagmicrobio.2026.117492_fur11","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1128\/AAC.01623-15","article-title":"Rapid In vitro evolution of Human Cytomegalovirus UL56 mutations that confer letermovir resistance","volume":"59","author":"Chou","year":"2015","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889326002427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889326002427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:05:46Z","timestamp":1791241546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889326002427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":176,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0732889326002427"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2026.117492","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiviral resistance testing for DNA viruses in immunocompromised patients: Mechanisms, clinical utility, and limitations","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2026.117492","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117492"}}